Revision History

1 revisions for "GLP-1 Drugs and Breast Cancer: What a 111,000-Woman Study Actually Shows — and What It Doesn't"

A large retrospective study from Penn Medicine, presented at the 2026 ASCO Annual Meeting, found that women taking GLP-1 medications like Ozempic had roughly 31% lower odds of developing breast cancer compared to non-users. But the observational design, unmeasured confounders, and lack of weight-change data leave open the central question: do the drugs themselves reduce cancer risk, or are healthier, wealthier patients simply more likely to take them?